Cleared Traditional

K871102 - O.1 TO 50.0% CARBON DIOXIDE, USP BALANCE NITRO.,NF (FDA 510(k) Clearance)

Class I Anesthesiology device.

K871102 · Matheson Gas Products, Inc. · Anesthesiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1987
Decision
32d
Days
Class 1
Risk

K871102 is an FDA 510(k) clearance for the O.1 TO 50.0% CARBON DIOXIDE, USP BALANCE NITRO.,NF. Classified as Gas, Calibration (specified Concentration) (product code BXK), Class I - General Controls.

Submitted by Matheson Gas Products, Inc. (East Rutheford, US). The FDA issued a Cleared decision on April 20, 1987 after a review of 32 days - a notably fast clearance cycle.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.6400 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Matheson Gas Products, Inc. devices

Submission Details

510(k) Number K871102 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 19, 1987
Decision Date April 20, 1987
Days to Decision 32 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
107d faster than avg
Panel avg: 139d · This submission: 32d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code BXK Gas, Calibration (specified Concentration)
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 868.6400
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.